年轻组的生长面积及总量明显高于老年组
△ 图a代表P3代,图b代表P8代
参考文献
1.Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?https://doi.org/10.1002/sctm.19-0202
2.https://www.marketscreener.com/quote/stock/MEDIPAL-HOLDINGS-CORPORAT-6492319/news/Medipal-Launch-of-TEMCELLR-HS-Inj-World-s-First-Mesenchymal-Stem-Cell-Product-for-GVHD-Treatment-21856924/
3.http://www.medi-post.com/cartistem/
4.http://pharmicell.com/eng/biz/medicine_cellgram.html
5.《干细胞制剂质量控制及临床前研究指导原则(试行)》国家卫生计生委办公厅、国家食品药品监管总局办公厅
6.The Analysis of In Vivo Aging in Human Bone Marrow Mesenchymal Stromal Cells Using Colony-Forming Unit-Fibroblast Assay and the CD45 low CD271 + Phenotype.https://doi.org/10.1155/2019/5197983
7.Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow-derived mesenchymal stem/stromal cells. https://doi.org/10.1002/sctm.20-0506
8. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.
https://doi.org/10.1080/14653240600855905
(▲上下滑动查看)